Skip to main content
Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors

Fig. 5

Effects of IT1208 treatment on TCR repertoire. TCR repertoires of the blood CD4+ and CD8+ T cells and the tumor tissues were analyzed using next-generation sequencing. a. Changes in the TCR repertoires of the blood CD4+ and CD8+ T cells following IT1208 treatment are shown as R similarity index. Lower similarity index indicates greater variation in TCR repertoire following IT1208 treatment. P values obtained by an unpaired, two-tailed Student’s t test. b. Changes in 1-Pielou clonality index of TCR repertoire in the blood CD8+ T cells. c. The sum total frequency of tumor-blood overlapping clones in blood CD8+ T cells. The clones overlapping between blood and tumor were identified at pre- and post-treatment, and the sum total frequency of these overlapping clones is plotted. d. Comparison of the changes in sum total frequency of Blood-Tumor overlapping clones between 0.1 mg/kg and 1 mg/kg group in blood CD8+ T cells. e. Scatter plot of the changes in the frequency of overlapping CD8+ T-cell clones in the blood and maximum change from baseline. Each dot represents individual patients. White and black represent 0.1 and 1.0 mg/kg IT1208 treatment, respectively. a and d Unpaired, two-tailed Student’s t test. (C) Paired, two-tailed Student’s t test for comparison within group, unpaired, two-tailed Student’s t test for comparison between groups. **, P < 0.01

Back to article page